May 2023 brings with it many endocrinology and diabetes conference opportunities. Notably, the Immunology of Diabetes Society Congress meeting as well as the American Association of Clinical Endocrinologists (AACE) annual meeting.

Several UCDC faculty and trainees are presenting at the 2023 Immunology of Diabetes Society Congress in Paris in May. Attendees will hear renowned speakers exposing the challenges and opportunities facing the Type 1 diabetes field, with state-of-the-art oral and poster presentations covering the most recent technical and scientific advances on the disease pathophysiology and treatment. Presentees include:

• Abdulaziz Almutairi: "Reduction of Macrophage-iPLA2β Derived Proinflammatory Lipids Inhibit Type 1 Diabetes Development" (oral presentation)
• Sasanka Ramanadham, Ph.D.: "Involvement of Macrophage iPLA2β-Derived Lipid Signals (iDLs) in the Emergence of Type 1 Diabetes" (oral presentation)
• Anath Shalev, M.D.: "Verapamil" (Symposium talk - Innovative interventions and preclinical development)
• Tayleur White: "Reducing iPLA2b Expression in T-lymphocytes Mitigates Type I Diabetes Development by Decreasing Proinflammatory Eicosanoids Production" (poster presentation)

Additionally, several Division of Endocrinology, Diabetes, and Metabolism fellows will presented their abstracts at the American Association of Clinical Endocrinology annual meeting May 9-11 in New Orleans. See the list below.

• Arya May: “Post-Bariatric Hypoglycemia (PBH) Refractory to Conventional Therapies: The Combined Effect of Very High Doses of Glucagon-Like Receptor Agonist (GLP1-RA) and a Low Dose of Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)”
• Mouna Gunda: “Rare cause of non-PTH mediated hypercalcemia due to pneumocystis pneumonia in renal transplant recipient”
• Sebastian Campana: “Efficacy and Safety of Glucose like Peptide-1 Receptor Agonist (GLP-1RA) in Patients with Diabetes who underwent Kidney Transplantation (KT): A Retrospective Study with a Control Group”
• Sravani Bantu: “Comparison of different Doses of Sodium-Glucose Ttransporter-2 Inhibitors (SGLT2i) to SGLT2i with Magnesium Infusions for Refractory Hypomagnesaemia in a patient with Monogenic Diabetes Type-5 (MODY-5).”

Be sure to add the above talks and poster presentations to your program scheduler to support fellow colleagues. If you have an upcoming presentation you would like to share, email diabetescomm@uabmc.edu.